AbbVie (NYSE: ABBV) recently presented landmark nine-year follow-up data from the Phase 3 CLL14 trial at the European Hematology Association 2026 meeting. The results confirm that a one-year fixed-duration venetoclax combination therapy provides a median of approximately eight years off treatment before requiring further intervention....
AbbVie (ABBV) has successfully transitioned from its Humira patent cliff by scaling its Skyrizi and Rinvoq immunology franchises, driving a 28% stock gain over the past year. The company recently announced an all-cash acquisition of clinical-stage biotech Apogee Therapeutics for nearly $11 billion to bolster...
AbbVie announced on June 8, 2026, that it will present new clinical data across its blood cancer portfolio at the European Hematology Association (EHA) 2026 Congress in Stockholm. The presentation includes six oral and multiple poster sessions highlighting advancements in multiple myeloma, follicular lymphoma, chronic...
AbbVie Inc., headquartered in North Chicago, maintains a substantial market capitalization of $356.4 billion while focusing its development and commercialization efforts on medicines within immunology, oncology, neuroscience, aesthetics, and eye care sectors. Although the stock has trailed the broader S&P 500 over the past year...
This article presents a comparative investment analysis between pharmaceutical giants AbbVie (ABBV) and Bristol-Myers Squibb (BMY), evaluating their growth potential, financial performance, and risk profiles for investors targeting 2026. The author concludes that AbbVie is the superior pick due to its focused operational strategy, faster...
